Farxiga (Dapagliflozin) Cost in New York: Prices, Insurance, and Savings in 2026

Dapagliflozin, marketed as Farxiga, is an SGLT2 (sodium-glucose cotransporter-2) inhibitor administered orally once daily in 10 mg tablets. The FDA has approved dapagliflozin for managing type 2 diabetes, reducing the risk of specific heart failure outcomes, and treating chronic kidney disease. Because the FDA label for dapagliflozin has been updated multiple times since its initial approval in 2014, you should verify the precise indication language and scope against the current label rather than relying on recollection.

Farxiga's manufacturer list price for a 30-day supply is close to $620 as of early 2026, but almost no insured New Yorker pays that figure. Commercially insured patients who activate AstraZeneca's copay card typically pay $0 to a capped amount per fill, New York Medicaid covers Farxiga with prior authorization, and Medicare Part D enrollees are now protected by a $2,000 annual out-of-pocket cap under the Inflation Reduction Act. The list price is a starting point for negotiation between the manufacturer, pharmacy benefit managers, and insurers, not a reliable estimate of what any individual patient will be charged at the counter.

There is no FDA-approved generic dapagliflozin tablet on the U.S. market as of this writing. That status can change with little notice once patent or exclusivity periods lapse, so anyone relying on this fact for a purchasing decision should confirm current generic availability at the time of filling a prescription.

What is established, what is plausible, and what is not established

Established: Farxiga's list price is set nationally by AstraZeneca and does not vary by New York county or borough; the AstraZeneca copay savings card exists and excludes patients on government insurance under federal anti-kickback rules; New York Medicaid requires prior authorization for Farxiga; the Inflation Reduction Act created a $2,000 annual out-of-pocket cap for Medicare Part D beginning in 2025; New York permits telehealth prescribing by state-licensed clinicians.

Plausible but not verifiable from the sources available here: exact current PBM rebate percentages, exact current savings-card annual caps, exact current cash prices at specific New York pharmacies, and current turnaround times for Medicaid managed care prior authorization decisions. These figures move throughout the year and were not independently confirmed against a primary source for this draft.

Not established: that compounded dapagliflozin is cheaper than brand Farxiga in New York as a general rule. Compounding cost depends on the pharmacy and formulation, and compounding is not intended as a cost-saving substitute for a commercially available product.

Why the list price rarely reflects what you pay

Pharmacy benefit managers negotiate rebates with manufacturers on behalf of insurers, and industry-wide data published by market research firms such as IQVIA have repeatedly shown that net prices for branded drugs, including SGLT2 inhibitors as a class, run well below list price after rebates are applied (IQVIA Institute). IQVIA does not publish a New York-specific or Farxiga-specific rebate figure that can be cited with precision here, so treat any specific percentage discount as an industry-average approximation rather than a guarantee for a given plan.

Cash-pay options if you have no prescription coverage

AstraZeneca's patient assistance program (branded AZ&Me) can provide Farxiga at no cost to qualifying patients based on household income relative to the federal poverty level. Discount cards such as GoodRx or RxSaver sometimes lower the cash price at participating New York pharmacies, but the discounted price varies by pharmacy and by month and should be checked at the time of fill rather than assumed from a prior visit.

New York Medicaid coverage for Farxiga

New York Medicaid covers Farxiga for its FDA-approved indications subject to prior authorization. The prescriber typically must document a confirmed diagnosis and, for type 2 diabetes, that first-line therapy such as metformin has been tried or is contraindicated. Prior authorization requests are processed through the patient's Medicaid managed care organization (for example, Healthfirst, Fidelis Care, or Amerigroup); exact turnaround times differ by plan and are not something this article can state with certainty for every MCO. If a request is denied, prescribers and patients can pursue a fair hearing appeal through the New York State Department of Health.

Clinical guideline bodies, including cardiology societies, have given SGLT2 inhibitors a strong recommendation for heart failure with reduced ejection fraction based on randomized trial evidence. The magnitude of benefit reported in the pivotal heart failure and chronic kidney disease trials for dapagliflozin (commonly referenced under the names DAPA-HF and DAPA-CKD) is substantial and has shaped both guideline recommendations and payer willingness to approve the drug, but the exact effect sizes, confidence intervals, and trial populations should be verified against the original published trials rather than repeated from secondary summaries. A search of the primary literature can be started at PubMed.

Insurance coverage beyond Medicaid

Most major commercial insurers operating in New York, including national carriers and New York-specific plans, place Farxiga on a preferred brand formulary tier, with a copay that commercial members can confirm through their plan's formulary lookup tool. Some employer-sponsored plans require step therapy with metformin before approving dapagliflozin for type 2 diabetes; step therapy is less commonly applied when the indication is heart failure or chronic kidney disease, since SGLT2 inhibitors do not have a direct oral substitute for those uses.

Medicare Part D

Medicare Part D plans cover Farxiga. Since 2025, the Inflation Reduction Act has capped total annual out-of-pocket drug spending for Part D enrollees at $2,000 (CMS). Depending on a beneficiary's plan design and any other medications they take, this cap can be reached well before the end of the calendar year, after which covered fills are provided without further cost sharing for that plan year. The exact month this occurs depends on the specific plan and the patient's full medication list, not on Farxiga alone.

How to confirm your own coverage before filling

Call the number on your insurance card or use your plan's online formulary tool and ask three questions: is dapagliflozin 10 mg covered, what tier is it on, and is prior authorization or step therapy required. Getting these answers before the prescription is sent to the pharmacy avoids an unexpected charge at pickup.

The AstraZeneca savings card

AstraZeneca offers a manufacturer copay card for eligible commercially insured patients that can reduce out-of-pocket cost substantially, sometimes to $0 per fill up to a per-fill and annual maximum. Patients enrolled in Medicare, Medicaid, Tricare, or VA benefits are not eligible, consistent with federal anti-kickback rules that apply broadly to manufacturer copay assistance. The exact per-fill cap and annual maximum are set by AstraZeneca and have changed in the past, so confirm the current terms directly with AstraZeneca or your pharmacy before assuming a specific dollar figure. Enrollment is typically available online or through a prescriber's office and the card activates automatically at participating pharmacies.

Verification checklist: what is stable versus what you must confirm today

Use this before relying on any cost figure in this article or elsewhere.

Stable facts (federal regulatory or clinical status; unlikely to change month to month):

• Dapagliflozin's FDA-approved drug class (SGLT2 inhibitor) and standard tablet formulation and once-daily dosing schedule, confirm current label details at FDA.
• Whether a compounded preparation requires a 503A-licensed pharmacy and an individualized patient-specific prescription under federal compounding law, confirm current requirements with the FDA and New York State Board of Pharmacy.
• That AstraZeneca copay cards are unavailable to patients on government insurance, a standing federal anti-kickback restriction.
• That the Medicare Part D $2,000 annual out-of-pocket cap took effect under the Inflation Reduction Act, verify current-year cap amount at CMS.
• That New York permits telehealth prescribing and requires commercial telehealth-visit parity under state insurance law, verify current statute text at NY DFS.

Date-sensitive facts (confirm at the time of your prescription, not from this article):

• The current cash/list price for a 30-day Farxiga supply at your specific pharmacy.
• Whether a generic dapagliflozin has since reached the U.S. market.
• The current AstraZeneca savings card per-fill and annual dollar caps.
• Your specific Medicaid managed care plan's current prior authorization criteria and processing timeline.
• Your specific commercial plan's formulary tier, copay amount, and any step-therapy requirement for dapagliflozin.
• Discount-card (GoodRx, RxSaver, etc.) pricing at a named New York pharmacy, which changes frequently and by location.
• The compounding pharmacy's current New York State license status and its USP 795/797 compliance, verifiable through the New York State Education Department's Office of the Professions.

Should dapagliflozin pricing information in this article differ from what your pharmacy or insurer provides, their current pricing takes precedence over the figures shown here.

Compounded dapagliflozin in New York

New York-licensed 503A compounding pharmacies may prepare dapagliflozin under a valid, patient-specific prescription when a prescriber documents an individualized medical need, such as a non-standard dose, an alternate dosage form for a patient with swallowing difficulty, or removal of a specific inactive ingredient causing an allergic reaction. Federal compounding law and New York State Board of Pharmacy oversight both frame 503A compounding as an individualized-need exception, not a bulk or cost-driven alternative to the commercially available product. Pricing at compounding pharmacies varies by formulation complexity and is not reliably lower than brand-name Farxiga; confirm both price and current state licensure directly with the pharmacy before proceeding.

Telehealth prescribing in New York

New York permits state-licensed physicians, nurse practitioners, and physician assistants to conduct a synchronous audio-video visit and issue an electronic prescription for Farxiga to any New York pharmacy. State insurance law requires commercial insurers to reimburse telehealth visits at parity with in-person visits; verify the current statutory citation and any recent amendments at the New York State Department of Financial Services rather than assuming it is unchanged from a prior year. Before a telehealth visit for dapagliflozin, having recent labs available (basic metabolic panel, hemoglobin A1c for diabetes, estimated glomerular filtration rate, and BNP or NT-proBNP if the indication is heart failure) allows the prescriber to confirm the indication without an in-person visit.

Monitoring costs beyond the drug itself

Dapagliflozin's FDA labeling recommends assessing renal function before starting treatment and periodically thereafter. Routine basic metabolic panels add a modest recurring cost that varies by lab and insurance status. SGLT2 inhibitors as a class are also associated with an increased risk of genital mycotic (yeast) infections; this is a mechanistically expected effect of increased urinary glucose excretion and has been reported across large outcome trials in this drug class, though the exact incidence reported for dapagliflozin specifically should be confirmed against the primary trial publication rather than a secondary summary. Over-the-counter antifungal treatment for a mycotic infection is a low-cost, self-limited expense if it occurs, but a new or worsening genital or urinary symptom, fever, or signs of a more serious infection warrants a call to the prescriber rather than self-treatment, and any signs of dehydration, ketoacidosis symptoms (nausea, vomiting, abdominal pain, unusual fatigue), or acute kidney symptoms warrant urgent medical evaluation.

How to get the lowest realistic price in New York

1. Check your formulary first. Confirm tier placement and whether prior authorization or step therapy applies before your prescriber sends the script.
2. Activate the AstraZeneca savings card if commercially insured. It stacks on top of your plan's negotiated price and often brings the copay close to $0, subject to per-fill and annual caps you should confirm directly with AstraZeneca.
3. Compare pharmacies. Cash and discount-card prices can differ meaningfully between pharmacies in the same ZIP code; call ahead or use a price-comparison tool.
4. Apply for patient assistance if uninsured and income-eligible. AZ&Me processing takes time, so start the application before you run out of medication.
5. Consider compounding only for a documented clinical need, not as a way to avoid brand pricing, and confirm the pharmacy's current New York licensure first.

Frequently asked questions

References

• U.S. Food and Drug Administration. Farxiga (dapagliflozin) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202293s024lbl.pdf
• Centers for Medicare & Medicaid Services. Inflation Reduction Act and Medicare Part D out-of-pocket cap. https://www.cms.gov
• New York State Department of Financial Services. Telehealth coverage parity requirements. https://www.dfs.ny.gov
• IQVIA Institute for Human Data Science. Industry reporting on net versus list drug pricing. https://www.iqvia.com
• PubMed, for locating and verifying primary trial publications on dapagliflozin (DAPA-HF, DAPA-CKD, DECLARE-TIMI 58) before citing specific effect sizes. https://pubmed.ncbi.nlm.nih.gov/

This article summarizes publicly available regulatory, coverage, and program information as of the date above. It does not constitute insurance, legal, or medical advice, and specific prices, coverage rules, and program terms should be confirmed directly with the relevant insurer, pharmacy, or manufacturer before making a treatment or purchasing decision.